Efficacy of thymosin combined with ipratropium bromide in treatmet of elderly patients with chronic obstructive pulmonary disease and severe pneumonia
Chen Ke
Zhang Wei
Du Long-yu
Abstract：Objective To investigate the efficacy of thymosin combined with ipratropium bromide in treatment of elderly patients with chronic obstructive pulmonary disease (COPD) and severe pneumonia. Methods A total of 90 senior patients with severe pneumonia and COPD admitted to Jinhua Central Hospital from April 2022 to January 2024 were selected as the research subjects. According to random number table method,these patients were divided into two groups with 45 in each group. In addition to standard comprehensive care,ipratropium bromide was administered to the patients in the control group while ipratropium bro-mide and thymosin injection were used in the observation group. Two patients fell off during treatment in both groups and thus 43 patients completed the study in both. The curative effect,clinical pulmonary infection score (CPIS),scores of acute physiological and chronic health evaluation Ⅱ (APACHE Ⅱ),inflammatory indexes (interleukin-1 receptor antagonist (IL-1Ra),monocyte Toll-like receptor 4 (TLR4),tissue inhibitor of metalloproteinase-1 (TIMP-1)),pulmonary function indexes (forced vital capacity (FVC),forced expiratory volume in 1 second/FVC (FEV1/FVC),peak expiratory flow (PEF)),immune function indexes (CD3+,CD4+,CD4+/CD8+) and adverse reactions in the two groups were compared before and after treatment. Results The total response rate in the observation group was 86.05％,which was significantly better than that of 67.44％ in the control ( x²=4.170,P=0.041). After treat-ment,CPIS,APACHE Ⅱ score,TIMP-1 and TLR4 in the observation group and control group were (4.63±0.71) points,(12.33±2.07) points,(132.59±12.50) ng·L-1,(44.32±7.15)％ and (5.35±0.73) points,(15.30±2.58) points,(144.37±14.46) ng·L-1,(53.23±8.19)％,lower than those before treatment ((8.15±1.82) points,(28.28±4.16) points,(183.48±27.32) ng·L-1,(82.46±3.74)％;(8.32±1.63) points,(27.69±4.25) points,(188.15±26.47) ng·L-1,(81.43±4.05)％),and the observation group's aforementioned in-dexes were lower than the control group's (P<0.05). IL-1Ra,FVC,FEV1/FVC,PEF,CD3+,CD4+and CD4+/CD8+in observation group and control group were (453.63±68.33) pg·mL-1,(2.59±0.32) L,(48.34±5.35)％,(3.38±0.53) L·s-1,(67.27±4.54)％,(40.59±3.50)％,(2.37±0.39) and (387.27±51.54) pg·mL-1,(2.25±0.28) L,(44.61±4.57)％,(2.86±0.45) L·s-1,(63.63±5.73)％,(35.37±4.46)％,(2.02±0.35),higher than those before treatment (287.33±39.63) pg·mL-1,(1.45±0.28) L,(37.23±5.78)％,(2.47±0.35) L·s-1,(55.48±5.26)％,(31.15±3.47)％,(1.63±0.35);(292.48±45.46) pg·mL-1,(1.41±0.23) L,(38.14±5.97)％,(2.42±0.36) L·s-1,(55.23±5.14)％,(31.48±3.32)％,(1.56±0.34)),the observation group's aforementioned indexes were greater than the control group's (P<0.05). The observation group's adverse reaction rate of 4.65％ was not statistically different from the control group's 2.33％ (x²=0.345,P=0.557). Conclusion Curative effect of thymosin combined with ipratropium bromide is good in elderly patients with COPD and severe pneumonia since it can improve inflammatory response,pulmonary function and immune function and has good safety.
Keywords：ThymosinIpratropium bromideChronic obstructive pulmonary diseaseSevere pneumoniaInterleukin-1 receptor antagonistMonocyte Toll-like receptor 4Tissue inhibitor of metalloproteinase-1
Publication Date：2024-12-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 699-703 )